나이관련황반변성에 대한 항혈관내피성장인자 14회 유리체내주사: 완료시기와 임상결과

• 영문명: Fourteen Anti-vascular Endothelial Growth Factor Injections for Age-related Macular Degeneration: Ending Period and Clinical Outcome
• 발행기관: 대한안과학회
• 저자명: 한재욱(Jae Wook Han) 김종우(Jong Woo Kim) 김철구(Chul Gu Kim) 이동원(Dong Won Lee) 한정일(Jung Il Han) 유영주(Young Ju Lew) 김재휘(Jae Hui Kim)
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume58,number9, 1~8쪽, 전체 8쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2017.09.30

영문 초록

Purpose: To evaluate the clinical course of patients who had completed 14 ranibizumab or aflibercept monocular treatments. Methods: Retrospective medical record analysis was performed to 24 patients who were diagnosed with monocular neovascular age-related macular degeneration and had completed 14 ranibizumab or aflibercept monocular injections, allowed by the Korean National Health Care system. Time to completion was measured along with the percentage and timing of medication switch. Best-corrected visual acuity (BCVA) was measured at the time of diagnosis, after 3-loading injections, and the time of completion. Additionally, we searched for any other factors that had influenced the time to completion. Results: The average time to completion of 14 injections was 32.3 ± 6.2 months (21–48 months). The switching was performed in 17 eyes (70.8%), and it was done after 9.4 ± 2.1 injections (4–14 injections) with prior medication. After 14 injections, the BCVA improved in 6 eyes (25.0%), unchanged in 8 eyes (33.3%), and worsened in 10 eyes (41.7%). Complete resolution of intraretinal fluid and subretinal fluid after 3 loading injections were observed in 20 eyes, and it was significantly related to time to the first recurrence and time to the completion of 14 injections (p = 0.007, r = 0.583). Conclusions: The average time to completion of 14 injections was 32.3 months, and switching of medication was performed in 70.8%. Longer time to the first recurrence was related to longer completion time. This study will provide useful facts when informing the patients their future treatment plans under the Korean Health Care system. J Korean Ophthalmol Soc 2017;58(9):1042-1049

키워드

Aflibercept Choroidal neovascularization Macular degeneration Ranibizumab